Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biological sampling.
- Who it may be relevant to
- Registry conditions: Myelodysplastic Syndromes, Ferroptosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
Detailed description
Myelodysplastic syndromes (MDS) are hematological malignancies characterized by a defect in blood cells production. Their pathophysiology remains poorly understood, but an excessive death of progenitor cells is considered as a key mechanism contributing to the appearance of cytopenia. Furthermore, it is known that there are abnormalities of iron metabolism in MDS, especially in patients with ring sideroblasts and SF3B1 mutation. The classical therapeutic strategy in MDS relies on symptomatic management of cytopenias (transfusions, growth factors) associated with demethylating agents in high-risk forms. Unfortunately, these treatments only stabilize the disease and only allogeneic bone marrow transplantation (reserved to limited number of patients) can cure the patients. Therefore, there is a urgent need to identify new therapeutic targets in these diseases.
An excessive apoptosis activation has been shown in MDS for a long time. However, other cell death pathways could also contribute to their pathophysiology. Among them, ferroptosis, a cell death process triggered by the accumulation of free iron in the cell, seems to be a promising candidate.
The project is proposed to study ferroptosis in SF3B1-mutant MDS patients. An additionnal bone marrow sample will be aspirate at diagnosis. Ferroptosis will be analyzed using flow cytometry (labeling of peroxidized lipids with C11-BODIPY). The percentage of cells in ferroptosis will be compared between SF3B1-mutant MDS patients and control patients (patients evaluated for Monoclonal Gammapathy of Unknown Significance-MGUS). The presence of an excess of ferroptosis in SF3B1-mutant MDS patients will be correlated to clinico-biological parameters. No follow up will be be performed.
Interventions
- Biological Biological sampling
The procedure will consist of an additional bone marrow sample and blood sample
Primary outcome measures
- Percentage of cells undergoing ferroptosis in SF3B1-mutant MDS patients compared to MGUS patients [Time frame: At Baseline]
Secondary outcome measures (3)
- Percentage of cells undergoing ferroptosis in the different bone marrow subpopulations (stem cells, progenitors, and erythroid and myeloid precursors at different stages of differentiation) of SF3B1-mutant MDS patients [Time frame: At Baseline]
- Biological characteristics of SF3B1-mutant MDS patients with an excess of cells undergoing ferroptosis in the bone marrow compared to MGUS controls [Time frame: At baseline]
- Clinical characteristics of SF3B1-mutant MDS patients with an excess of cells undergoing ferroptosis in the bone marrow compared to MGUS controls [Time frame: Through study completion, up to 2 years]
Eligibility criteria
Inclusion criteria
For all :
- Patients of legal age (age ≥ 18 years)
- Subjects affiliated to or benefiting from a social security scheme
- Free, written and informed consent signed by the participant and the investigator
For MDS patients :
- Sampling at diagnosis for MDS patients (WHO 2016 criteria)
- Presence of ring sideroblasts on bone marrow smear
For MGUS patients :
\- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).
Exclusion criteria
For all
- Patient transfused with red blood cells within 120 days prior to collection
- Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection
- Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda
- Person under a legal protection measure (legal protection, guardianship or curatorship)
- Person deprived of liberty by judicial or administrative decision
- Person who is unable to give consent
- Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 3 centers
- CHU de Bordeaux, Laboratoire d'Hématologie — Pessac
- CHU de Bordeaux, Service de Médecine Interne — Pessac
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire — Pessac
Identifiers
NCT: NCT05924074 · CHUBX 2022/43